Works matching DE "MOLNUPIRAVIR"
Results: 194
Molnupiravir: Mutagenität wirkt virostatisch: Pharmakologie.
- Published in:
- Chemie in unserer Zeit, 2022, v. 56, n. 1, p. 8, doi. 10.1002/ciuz.202110039
- Publication type:
- Article
Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry.
- Published in:
- Antibiotics (2079-6382), 2022, v. 11, n. 11, p. 1541, doi. 10.3390/antibiotics11111541
- By:
- Publication type:
- Article
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent.
- Published in:
- Antibiotics (2079-6382), 2021, v. 10, n. 11, p. 1294, doi. 10.3390/antibiotics10111294
- By:
- Publication type:
- Article
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
- Published in:
- Vaccines, 2022, v. 10, n. 10, p. N.PAG, doi. 10.3390/vaccines10101731
- By:
- Publication type:
- Article
Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression.
- Published in:
- Vaccines, 2022, v. 10, n. 7, p. N.PAG, doi. 10.3390/vaccines10071141
- By:
- Publication type:
- Article
A study survey on molnupiravir treatment in COVID-19 patients at home in Ninh Thuan province, Vietnam.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2024, v. 28, n. 1, p. 433
- By:
- Publication type:
- Article
Editorial: Fighting fire with fire: Using non-pathogenic viruses to control unrelated infections.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1046851
- By:
- Publication type:
- Article
Molnupiravir is effective in patients with haematological malignancies.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 6, p. 1251, doi. 10.1002/ijc.34442
- By:
- Publication type:
- Article
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34839-9
- By:
- Publication type:
- Article
SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-32045-1
- By:
- Publication type:
- Article
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the Omicron era.
- Published in:
- Expert Review of Clinical Pharmacology, 2023, v. 16, n. 11, p. 1017, doi. 10.1080/17512433.2023.2267973
- By:
- Publication type:
- Article
Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
- Published in:
- PLoS ONE, 2024, v. 19, n. 6, p. 1, doi. 10.1371/journal.pone.0298254
- By:
- Publication type:
- Article
Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 14, p. 11237, doi. 10.3390/ijms241411237
- By:
- Publication type:
- Article
Evaluation of In Vitro Distribution and Plasma Protein Binding of Selected Antiviral Drugs (Favipiravir, Molnupiravir and Imatinib) against SARS-CoV-2.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 3, p. 2849, doi. 10.3390/ijms24032849
- By:
- Publication type:
- Article
Correction: Sharov et al. Computational Analysis of Molnupiravir. Int. J. Mol. Sci. 2022, 23 , 1508.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Computational Analysis of Molnupiravir.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 3, p. 1508, doi. 10.3390/ijms23031508
- By:
- Publication type:
- Article
Molnupiravir.
- Published in:
- Australian Prescriber, 2022, v. 45, n. 2, p. 60, doi. 10.18773/austprescr.2022.014
- Publication type:
- Article
Erratum.
- Published in:
- 2023
- Publication type:
- Correction Notice
Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 9, p. 2119, doi. 10.1093/jac/dkae163
- By:
- Publication type:
- Article
Comment on: Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 7, p. 1717, doi. 10.1093/jac/dkae124
- By:
- Publication type:
- Article
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors' response.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 12, p. 3009, doi. 10.1093/jac/dkad336
- By:
- Publication type:
- Article
Is molnupiravir a wise investment? Reassessing COVID-19 treatment strategies.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 11, p. 2779, doi. 10.1093/jac/dkad275
- By:
- Publication type:
- Article
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 9, p. 2131, doi. 10.1093/jac/dkad216
- By:
- Publication type:
- Article
Non-randomized evaluation of hospitalization after a prescription for nirmatrelvir/ritonavir versus molnupiravir in high-risk COVID-19 outpatients.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 7, p. 1683, doi. 10.1093/jac/dkad154
- By:
- Publication type:
- Article
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 7, p. 1586, doi. 10.1093/jac/dkad132
- By:
- Publication type:
- Article
Evaluation of publication bias for 12 clinical trials of molnupiravir to treat SARS-CoV-2 infection in 13 694 patients with meta-analysis.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2023, v. 78, n. 3, p. 613, doi. 10.1093/jac/dkac440
- By:
- Publication type:
- Article
Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel.
- Published in:
- Epidemiologia, 2023, v. 4, n. 3, p. 309, doi. 10.3390/epidemiologia4030031
- By:
- Publication type:
- Article
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
- Published in:
- Communications Biology, 2022, v. 5, n. 1, p. 1, doi. 10.1038/s42003-022-04322-8
- By:
- Publication type:
- Article
Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 8, p. 2303, doi. 10.3390/jcm13082303
- By:
- Publication type:
- Article
Molnupiravir as the COVID-19 panacea: false beliefs in low- and middle-income countries.
- Published in:
- Pathogens & Global Health, 2023, v. 117, n. 6, p. 525, doi. 10.1080/20477724.2023.2232593
- By:
- Publication type:
- Article
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
- Published in:
- Science Translational Medicine, 2022, v. 14, n. 628, p. 1, doi. 10.1126/scitranslmed.abl7430
- By:
- Publication type:
- Article
Molnupiravir: an oral treatment to add to the COVID-19 arsenal.
- Published in:
- Australian Journal of Pharmacy, 2022, v. 103, n. 1215, p. 74
- By:
- Publication type:
- Article
4′-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness.
- Published in:
- DNA & Cell Biology, 2022, v. 41, n. 8, p. 699, doi. 10.1089/dna.2022.0312
- By:
- Publication type:
- Article
Highly sensitive high‐performance thin‐layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations.
- Published in:
- Journal of Separation Science, 2022, v. 45, n. 14, p. 2582, doi. 10.1002/jssc.202200178
- By:
- Publication type:
- Article
Molnupiravir, a New Antiviral Drug for the Treatment of COVID-19.
- Published in:
- Eurasian Journal of Critical Care, 2022, v. 4, n. 3, p. 116, doi. 10.55994/ejcc.1112050
- By:
- Publication type:
- Article
Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study.
- Published in:
- Journal of Pharmaceutical Health Care & Sciences, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40780-024-00376-4
- By:
- Publication type:
- Article
A Green Voltammetric Determination of Molnupiravir Using a Disposable Screen-Printed Reduced Graphene Oxide Electrode: Application for Pharmaceutical Dosage and Biological Fluid Forms.
- Published in:
- Chemosensors, 2023, v. 11, n. 9, p. 471, doi. 10.3390/chemosensors11090471
- By:
- Publication type:
- Article
Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma.
- Published in:
- Biomedicines, 2023, v. 11, n. 9, p. 2356, doi. 10.3390/biomedicines11092356
- By:
- Publication type:
- Article
Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.1072202
- By:
- Publication type:
- Article
Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes: A target trial emulation study.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4653, doi. 10.1111/dom.15830
- By:
- Publication type:
- Article
Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis.
- Published in:
- Animals (2076-2615), 2024, v. 14, n. 9, p. 1322, doi. 10.3390/ani14091322
- By:
- Publication type:
- Article
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.
- Published in:
- Leukemia & Lymphoma, 2023, v. 64, n. 5, p. 1054, doi. 10.1080/10428194.2023.2183732
- By:
- Publication type:
- Article
On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia.
- Published in:
- Clinical & Experimental Medicine, 2023, v. 23, n. 7, p. 4033, doi. 10.1007/s10238-023-01010-7
- By:
- Publication type:
- Article
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic.
- Published in:
- Clinical & Experimental Medicine, 2023, v. 23, n. 6, p. 2715, doi. 10.1007/s10238-022-00949-3
- By:
- Publication type:
- Article
In Vitro Study of the Cytotoxic and Immunotropic Effects of Molnupiravir and Favipiravir.
- Published in:
- Pharmaceutical Chemistry Journal, 2024, v. 57, n. 11, p. 1693, doi. 10.1007/s11094-024-03066-5
- By:
- Publication type:
- Article
Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir.
- Published in:
- Toxicological Sciences, 2024, v. 202, n. 2, p. 278, doi. 10.1093/toxsci/kfae112
- By:
- Publication type:
- Article
Review on analytical and bioanalytical approaches for the estimation of two anti-Covid-19 drugs.
- Published in:
- Delta University Scientific Journal, 2024, v. 7, n. 1, p. 69, doi. 10.21608/dusj.2024.250731.1039
- By:
- Publication type:
- Article
Can Tremor Be a Rare Side Effect Related to Molnupiravir?
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2022, v. 11, p. 289, doi. 10.4274/mjima.galenos.2022.2022.38
- By:
- Publication type:
- Article
Synthesis of molnupiravir (MK-4482, EIDD-2801): a promising oral drug for the treatment of COVID-19 starting from cytidine.
- Published in:
- Nucleosides, Nucleotides & Nucleic Acids, 2023, v. 42, n. 6, p. 427, doi. 10.1080/15257770.2022.2153140
- By:
- Publication type:
- Article
Virology and safety profile of Molnupiravir at three different doses for treatment of SARS‐CoV‐2: a systematic review and meta‐analysis.
- Published in:
- APMIS, 2024, v. 132, n. 3, p. 139, doi. 10.1111/apm.13373
- By:
- Publication type:
- Article